ResMed Inc. (NYSE:RMD)
Q4 2024 Earnings Conference Call
August 031, 2024, 04:30 PM ET

Company Participants

Amy Wakeham - Chief Communications and Investor Relations Officer
Michael Farrell - Chief Executive Officer
Brett Sandercock - Chief Financial Officer

Conference Call Participants

Lyanne Harrison - Bank of America
Steven Wheen - Jarden
Brett Fishbin - KeyBanc
Michael Matson - Needham & Company
Dan Hurren - MST Marquee
David Bailey - Macquarie
Gretel Janu - E&P
Suraj Kalia - Oppenheimer
Margaret Kaczor-Andrew - William Blair
Anthony Petrone - Mizuho Group
Saul Hadassin - Barrenjoey Capital

Operator

Hello, and welcome to the Q4 Fiscal Year 2024 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] Please note this conference call is being recorded. I'll now turn the call over to Amy Wakeham, Chief Investor Relations Officer. Please go ahead, Amy.

Amy Wakeham

Great. Thank you, Kevin. Hello everyone. Welcome to ResMed's fourth quarter fiscal year 2024 earnings call. We are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today.

Our earnings press release and presentation are both available online now. During today's call, we will discuss several non-GAAP measures that we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for the GAAP financial information.

We encourage you to review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers. In addition, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance.

We make these statements based on our reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today.

I'll now turn the call over to our Chairman and CEO, Mick Farrell.

Michael Farrell

Thanks Amy, and thank you to our shareholders for joining us as we announce results from our full fiscal year 2024 and review our fourth quarter results in more detail. Our global ResMed team executed incredibly well in our fourth quarter, producing another strong period of growth and execution across our business.

With solid performance across all regions and all segments of our business and strong double-digit bottom-line growth. Ongoing new patient demand for our market leading flow generators remained robust in the quarter, even against a very tough year-over-year comparable. Media interest in sleep apnea and all the various therapies seems to be helping patients find their way to screening, diagnosis and therapy.